Physician profile
Lindsey E Axt
NPI 1356759732
$51,642.88
in general payments reported to CMS, 2019-2025
33 companies · $25K in 2025
The $25K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,385 · 2022: $1,576 · 2023: $3,148 · 2024: $21K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $12K · Travel and Lodging: $2,034 · Consulting Fee: $1,450 · Education: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,839.00 |
| Food and Beverage | $11,965.38 |
| Travel and Lodging | $2,033.60 |
| Consulting Fee | $1,450.00 |
| Education | $393.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,045.72 | 2021-2025 | |
| Janssen Biotech, INC. | $17,512.33 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $1,844.48 | 2021-2025 | |
| Lilly USA, LLC | $1,068.94 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $1,010.35 | 2021-2025 | Sotyktu |
| Incyte Corporation | $939.11 | 2021-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $898.92 | 2022-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $857.48 | 2021-2025 | Siliq, Cabtreo, Jublia |
| Regeneron Healthcare Solutions, INC. | $821.39 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $798.87 | 2021-2025 | Winlevi, Blu-U, Odomzo |
| Pfizer INC. | $746.46 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $630.36 | 2021-2025 | |
| Ucb, INC. | $539.21 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $489.76 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $352.63 | 2021-2025 | Nemluvio, Aklief, Epsolay |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $262.89 | 2023-2024 | Vtama |
| Amgen INC. | $155.30 | 2022-2025 | Otezla, Otezla |
| Biofrontera INC. | $136.40 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Epi Health, LLC | $79.02 | 2021-2022 | |
| Fidia Pharma USA INC. | $70.47 | 2024-2025 | |
| Botanix Sb INC | $55.58 | 2025 | Sofdra |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Almirall LLC | $53.15 | 2022-2025 | Klisyri, Seysara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.28 | 2022-2025 | Spevigo |
| Journey Medical Corporation | $27.45 | 2022-2023 | |
| Nabriva Therapeutics, Plc | $26.93 | 2022 | |
| Organon LLC | $26.92 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $20.53 | 2025 | |
| Genentech USA, INC. | $15.23 | 2022 | |
| Fresenius Kabi USA, LLC | $15.00 | 2023 | |
| Organogenesis INC. | $14.93 | 2023 | Puraply |
| Verrica Pharmaceuticals INC. | $14.07 | 2023 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Axt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.